Patents by Inventor Leonardo SIBILIO

Leonardo SIBILIO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ERBB2-targeting antibody
    Patent number: 11220553
    Abstract: The present invention relates to an antibody, particularly a monoclonal antibody, which binds a novel epitope of the ERBB2 tyrosine kinase receptor, wherein the unique features of said binding enable interference with receptor-mediated signalling and downstream biological effects in a novel and unanticipated fashion not obtainable with state-of-the-art therapeutic antibodies. The present invention relates to compositions comprising such an antibody and its humanized derivative, as well as methods using such an antibody and derivative, particularly in ERBB2-low/non-amplified breast cancers, particularly in combination with Trastuzumab and Pertuzumab.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: January 11, 2022
    Assignee: ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A.
    Inventors: Leonardo Sibilio, Patrizio Giacomini
  • MULTISTEP TUMOR TARGETING BY TAGGED ANTIBODY DERIVATIVES AND TAGGED DRUGS
    Publication number: 20200030455
    Abstract: The present invention primarily relates to a novel, flexible, modular, multi-step, targeted and conditional drug targeting and delivery system. This system bypasses some general limitations of Antibody Drug Conjugates (ADCs) and widens the applicability of these key anticancer agents in precision medicine.
    Type: Application
    Filed: January 26, 2018
    Publication date: January 30, 2020
    Inventors: Joachim BERTRAM, Karlheinz FRIEDRICH, Leonardo SIBILIO, Fabio CENTOLA, Patrizio GIACOMINI
  • Purification of bone morphogenetic proteins (BMPs)
    Patent number: 10428130
    Abstract: The present invention relates to a method for purifying a protein belonging to the transforming growth factor-? (TGF-?) superfamily, said method comprising subjecting a cell culture medium containing the protein to a Hydrophobic Charge 5 Interaction Chromatography (HCIC).
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: October 1, 2019
    Assignee: ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A.
    Inventors: Fabio Centola, Leonardo Sibilio
  • ERBB2-TARGETING ANTIBODY
    Publication number: 20190112387
    Abstract: The present invention relates to an antibody, particularly a monoclonal antibody, which binds a novel epitope of the ERBB2 tyrosine kinase receptor, wherein the unique features of said binding enable interference with receptor-mediated signalling and downstream biological effects in a novel and unanticipated fashion not obtainable with state-of-the-art therapeutic antibodies. The present invention relates to compositions comprising such an antibody and its humanized derivative, as well as methods using such an antibody and derivative, particularly in ERBB2-low/non-amplified breast cancers, particularly in combination with Trastuzumab and Pertuzumab.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 18, 2019
    Inventors: Leonardo SIBILIO, Patrizio GIACOMINI
  • PURIFICATION OF BONE MORPHOGENETIC PROTEINS (BMPS)
    Publication number: 20180111973
    Abstract: The present invention relates to a method for purifying a protein belonging to the transforming growth factor-? (TGF-?) superfamily, said method comprising subjecting a cell culture medium containing the protein to a Hydrophobic Charge 5 Interaction Chromatography (HCIC).
    Type: Application
    Filed: March 16, 2016
    Publication date: April 26, 2018
    Applicant: ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A.
    Inventors: Fabio CENTOLA, Leonardo SIBILIO